The risk of myopathy can be minimized by detecting and monitoring the most vulnerable patients, and by avoiding possible drug interactions due to the concomitant administration of medicines that inhibit transport proteins (OATP, P-gp) and some CYP450 isoenzymes (such as cyclosporin, tacrolimus, macrolides, azole antimycotics, some calcium antagonists, and HIV protease inhibitors). This evidence concerns the gene SLCO1A2 and myopathy.